“adeno-associated-virus” Archives

in
Entry Author Date Location
Novartis Pays $75M to Get Hands on Sangamo’s Zinc Fingers for Drug R&D 07/30/20 San Francisco
Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq 05/22/20 National
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus 01/29/20 Boston
Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report 01/28/20 National
Generation Bio Pockets $110M for Next Wave of Gene Therapy, IPO Plans 01/13/20 Boston
FDA Again Halts Solid Bio’s Duchenne Gene Therapy Clinical Trial 11/12/19 Boston
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits 06/26/19 San Francisco
How an Ohio Kids’ Hospital Quietly Became Ground Zero for Gene Therapy 04/15/19 National
Passage Bio Gets $116M As Wilson, Yamada Team Up On Gene Therapy Again 02/14/19 National
Neurogene Emerges with $68M to Advance Gene Therapies to the Clinic 02/12/19 New York
Sarepta’s Data Are First in Rush for Duchenne Gene Therapy 06/19/18 Boston
Novartis Bets $8.7B on AveXis’s Gene Therapy for Spine Disease 04/09/18 National
After Paper Shakes Sector, Gene Therapy Leader Jim Wilson Talks Safety 01/30/18 National
Homology Med Bags $83.5M More, Fueling Push For Gene Editing Twist 08/01/17 Boston
Nonprofit Seeds Exonics to Fund Push For CRISPR Duchenne Treatment 02/27/17 Boston
More Gene Therapy Momentum as Startup Avrobio Grabs $25M From Atlas, SV 08/02/16 Boston
Biogen Turns To UPenn Gene Therapy Pioneers in Wide-Ranging Alliance 05/16/16 Boston
With $43.5M Startup Cash, Homology Med Chases New Gene Editing Twist 05/02/16 Boston
CRISPR Hits Wall Street as Editas Bags $94M in IPO 02/02/16 Boston
Seeking A Fresh Start in Gene Therapy, Avalanche Merges With Annapurna 02/01/16 San Francisco
Biogen Helps Put $42.5M Into a Father’s Duchenne Gene Therapy Quest 11/05/15 Boston
Gene Therapy Startup Dimension Cuts Price But Bags $72M in IPO 10/21/15 Boston
Voyager Charts an IPO Course Amid Choppy Biotech Waters 10/11/15 Boston
Amid Nobel Prize Suspense, Making Sense Of Latest Gene-Editing News 10/06/15 National
Gene Therapy Startup Dimension Tx Takes Crossover Cash to IPO Queue 09/14/15 Boston
Shire Sends Hemophilia Gene Editing Prospects Back to Sangamo 09/02/15 San Francisco
Biogen Offers Up To $1 Billion for AGTC’s Ophthalmology Gene Therapy 07/02/15 Boston
Selecta Takes Nanotech to Gene Therapy, Celiac With New Deals 05/13/15 Boston
Gene Therapy Upstart Dimension Nabs $65M From “Crossover” Backers 04/21/15 Boston
Hunting for an IPO? Voyager Gets $60M From “Crossover” Backers 04/13/15 Boston
Page 1 of 2 next page »